Literature DB >> 20360501

Ninety-day mortality after intertrochanteric hip fracture: does provider volume matter?

Mary L Forte1, Beth A Virnig, Marc F Swiontkowski, Mohit Bhandari, Roger Feldman, Lynn E Eberly, Robert L Kane.   

Abstract

BACKGROUND: Research on the relationship between orthopaedic volume and outcomes has focused almost exclusively on elective arthroplasty procedures. Geriatric patients who have sustained an intertrochanteric hip fracture are older and have a heavier comorbidity burden in comparison with patients undergoing elective arthroplasty; therefore, any advantage of provider volume in terms of mortality could be overwhelmed by the severity of the hip fracture condition itself. This study examined the association between surgeon and hospital volumes of procedures performed for the treatment of intertrochanteric hip fractures in Medicare beneficiaries and inpatient through ninety-day postoperative mortality.
METHODS: The Medicare 100% files of hospital and physician claims plus the beneficiary enrollment files for 2000 through 2002 identified beneficiaries who were sixty-five years of age or older and who underwent inpatient surgery for the treatment of an intertrochanteric hip fracture with internal fixation. Provider volumes of intertrochanteric hip fracture cases were calculated with use of unique surgeon and hospital provider numbers in the claims. Fixed effects regression analysis using generalized estimating equations was used to model the association between hospital and surgeon intertrochanteric hip fracture volume and inpatient through ninety-day mortality, controlling for age, sex, race, Charlson comorbidity score, subtrochanteric fracture, prefracture nursing home residence, Medicaid-administered assistance, surgical device, and year. The unadjusted inpatient, thirty, sixty, and ninety-day mortality rates and adjusted relative risks are reported.
RESULTS: Between March 1, 2000, and December 31, 2002, 192,365 claims met inclusion criteria and matched with provider information. The unadjusted inpatient, thirty-day, sixty-day, and ninety-day mortality rates were 2.91%, 7.92%, 12.34%, and 15.19%, respectively. Patients managed at lower-volume hospitals had significantly higher (10% to 20%) adjusted risks of inpatient mortality than those managed at the highest-volume hospitals. By sixty days postoperatively, the increased mortality risk persisted only among patients managed at the lowest-volume hospitals (six cases per year or fewer). Patients who were managed by surgeons who treated an average of two or three cases per year had the highest mortality risks when compared with patients managed by the highest-volume surgeons.
CONCLUSIONS: Only the highest-volume hospitals showed an inpatient mortality benefit for Medicare patients with intertrochanteric hip fractures. Unlike the situation with elective arthroplasty procedures, our findings do not indicate a need to direct patients with routine hip fractures exclusively to high-volume centers, although the higher mortality rates found in the lowest-volume hospitals warrant further investigation.

Entities:  

Mesh:

Year:  2010        PMID: 20360501     DOI: 10.2106/JBJS.H.01204

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  23 in total

1.  Hospital Characteristics, Inpatient Processes of Care, and Readmissions of Older Adults with Hip Fractures.

Authors:  Nabil M Elkassabany; Molly Passarella; Samir Mehta; Jiabin Liu; Mark D Neuman
Journal:  J Am Geriatr Soc       Date:  2016-06-28       Impact factor: 5.562

2.  Editorial: large database studies--what they can do, what they cannot do, and which ones we will publish.

Authors:  Jonathan N Grauer; Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2015-02-28       Impact factor: 4.176

3.  In-hospital mortality after hip fracture by treatment setting.

Authors:  Katie J Sheehan; Boris Sobolev; Pierre Guy; Lisa Kuramoto; Suzanne N Morin; Jason M Sutherland; Lauren Beaupre; Donald Griesdale; Michael Dunbar; Eric Bohm; Edward Harvey
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

4.  Surgical time of day does not affect outcome following hip fracture fixation.

Authors:  Julie A Switzer; Ryan E Bennett; David M Wright; Sandy Vang; Christopher P Anderson; Andrea J Vlasak; Steven R Gammon
Journal:  Geriatr Orthop Surg Rehabil       Date:  2013-12

5.  Are Case Volume and Facility Complexity Level Associated With Postoperative Complications After Hip Fracture Surgery in the Veterans Affairs Healthcare System?

Authors:  Jimmy K Wong; T Edward Kim; Seshadri C Mudumbai; Stavros G Memtsoudis; Nicholas J Giori; Steven K Howard; Roberta K Oka; Robert King; Edward R Mariano
Journal:  Clin Orthop Relat Res       Date:  2019-01       Impact factor: 4.176

Review 6.  In-hospital mortality risk of intertrochanteric hip fractures: a comprehensive review of the US Medicare database from 2005 to 2010.

Authors:  E Kiriakopoulos; F McCormick; B U Nwachukwu; B J Erickson; J Caravella
Journal:  Musculoskelet Surg       Date:  2017-03-02

7.  The trends in treatment of femoral neck fractures in the Medicare population from 1991 to 2008.

Authors:  Benjamin J Miller; Xin Lu; Peter Cram
Journal:  J Bone Joint Surg Am       Date:  2013-09-18       Impact factor: 5.284

8.  Modeling the volume-effectiveness relationship in the case of hip fracture treatment in Finland.

Authors:  Reijo Sund
Journal:  BMC Health Serv Res       Date:  2010-08-13       Impact factor: 2.655

9.  The 1-year mortality of patients treated in a hip fracture program for elders.

Authors:  Scott Schnell; Susan M Friedman; Daniel A Mendelson; Karilee W Bingham; Stephen L Kates
Journal:  Geriatr Orthop Surg Rehabil       Date:  2010-09

Review 10.  Aligning Patient Acuity With Resource Intensity After Major Surgery: A Scoping Review.

Authors:  Tyler J Loftus; Jeremy A Balch; Matthew M Ruppert; Patrick J Tighe; William R Hogan; Parisa Rashidi; Gilbert R Upchurch; Azra Bihorac
Journal:  Ann Surg       Date:  2022-02-01       Impact factor: 13.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.